乳头状肾细胞癌中的程序性死亡受体配体1（PD-L1）表达
PD-L1 expression in papillary renal cell carcinoma.
作者信息
Motoshima Takanobu, Komohara Yoshihiro, Ma Chaoya, Dewi Arni Kusuma, Noguchi Hirotsugu, Yamada Sohsuke, Nakayama Toshiyuki, Kitada Shohei, Kawano Yoshiaki, Takahashi Wataru, Sugimoto Masaaki, Takeya Motohiro, Fujimoto Naohiro, Oda Yoshinao, Eto Masatoshi
机构信息
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
出版信息
BMC Urol. 2017 Jan 13;17(1):8. doi: 10.1186/s12894-016-0195-x.
BACKGROUND
The immune escape or tolerance of cancer cells is considered to be closely involved in cancer progression. Programmed death-1 (PD-1) is an inhibitory receptor expressed on activating T cells, and several types of cancer cells were found to express PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2).
METHODS
In the present study, we investigated PD-L1/2 expression in papillary renal cell carcinoma (pRCC).
RESULT
We found PD-L1 expression in 29 of 102 cases, but no PD-L2 expression was seen. PD-L1 expression was not significantly correlated with any clinicopathological factor, including progression-free survival and overall survival. The frequency of PD-L1-positive cases was higher in type 2 (36%) than in type 1 (22%) pRCC; however, there was no significant difference in the percentages of score 0 cases (p value = 0.084 in Chi-square test). The frequency of high PD-L1 expression cases was higher in type 2 (23%) than in type 1 (11%), and the frequency of high PD-L1 expression cases was higher in grade 3/4 (21%) than in grade 1/2 (13%). However, no significant association was found between PD-L1 expression and all clinicopathological factors in pRCC.
CONCLUSION
High expression of PD-L1 in cancer cells was potentially associated to highly histological grade of malignancy in pRCC. The evaluation of the PD-L1 protein might still be useful for predicting the efficacy of anti-cancer immunotherapy using immuno-checkpoint inhibitors, however, not be useful for predicting the clinical prognosis.
背景
癌细胞的免疫逃逸或耐受被认为与癌症进展密切相关。程序性死亡受体1（PD - 1）是一种在活化T细胞上表达的抑制性受体，并且发现几种类型的癌细胞表达PD - 1配体1（PD - L1）和配体2（PD - L2）。
方法
在本研究中，我们调查了乳头状肾细胞癌（pRCC）中PD - L1/2的表达情况。
结果
我们在102例病例中的29例中发现了PD - L1表达，但未观察到PD - L2表达。PD - L1表达与任何临床病理因素均无显著相关性，包括无进展生存期和总生存期。2型（36%）pRCC中PD - L1阳性病例的频率高于1型（22%）；然而，0分病例的百分比无显著差异（卡方检验p值 = 0.084）。2型（23%）中高PD - L1表达病例的频率高于1型（11%），3/4级（21%）中高PD - L1表达病例的频率高于1/2级（13%）。然而，在pRCC中未发现PD - L1表达与所有临床病理因素之间存在显著关联。
结论
癌细胞中PD - L1的高表达可能与pRCC的高组织学恶性程度相关。PD - L1蛋白的评估可能仍有助于预测使用免疫检查点抑制剂的抗癌免疫治疗的疗效，然而，对预测临床预后并无帮助。
Zotero 插件